Clinical Trial Detail

NCT ID NCT02049801
Title MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bruno C. Medeiros, National Cancer Institute (NCI)
Indications

acute myeloid leukemia

Therapies

Binimetinib + Cytarabine + Idarubicin

Age Groups: adult senior

Additional content available in CKB BOOST